The EMA Management Board adopted the Agency's 2025 annual report, highlighting strong performance in medicines approvals, and noted the draft roadmap for implementing electronic product information across the EU.

Global pharmaceutical companies are ramping up investments in China to capitalize on the nation's new five-year plan prioritizing biomedicine and emerging industries.

The EMA Management Board reviewed progress on new EU pharmaceutical legislation governance, adopted the 2025 annual report, and advanced the electronic product information roadmap for medicines.[1]

The China-ASEAN Regional Medical Products Trading Platform finalized its inaugural 2026 transaction worth over 10 million yuan between Qilu Pharmaceutical and a Thai buyer, enhancing cross-border pharma trade.

The EMA Management Board confirmed the near-complete setup of governance structures for new EU pharmaceutical legislation implementation and outlined a roadmap for mandatory electronic product information.

Hong Kong solidifies its role as a key financial center for Chinese biotech firms, enabling repeat capital raises and IPOs amid surging global deal flows.

EU co-legislators have finalized a provisional deal on the pharmaceutical reform package, modernizing regulations for the first time in 20 years to enhance medicine availability, affordability, innovation, and supply chain resilience across Europe.

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) announced that the US Food and Drug Administration

Japan recorded the highest number of US FDA novel-drug approvals among Asian markets from 2015-2023, driven by robust regulatory frameworks and global integration, according to McKinsey.

The EMA Management Board confirmed the governance structure for new EU pharmaceutical legislation is largely in place, alongside adoption of the 2025 annual report and preparations for electronic product information rollout.